Cellular Dynamics (ICEL)

[noretreat]

back in at the right time!

yay!

[TigerCloud]

And what about the investigation?

[LORTAP KCOTS]

if you shorted this today, you would be in a hot mess, Fujifilm is buying all of ICEL for $16.50 a share.

[TigerCloud]

There is no way this is going to hold its gains, take profits now, if I had the money, I would be shorting this so hard.

[uptowndw]

Wow congrats to the longs here!!!!!

[noretreat]

finally back on track here...anyone want to give us a target price?

[XenaLives]

About half of the shorts were covered on tax loss selling..

 
 Settlement Date	Short Interest	Avg Daily Share Volume	Days To Cover 
 2/13/2015	337,678	44,020	7.671013 
 1/30/2015	364,547	49,248	7.402270 
 1/15/2015	345,576	34,094	10.135977 
 12/31/2014	325,349	88,832	3.662520 
 12/15/2014	569,470	75,370	7.555659 
 11/28/2014	538,039	21,801	24.679556 
 11/14/2014	543,771	20,524	26.494397 
 10/31/2014	575,352	29,403	19.567799 
 10/15/2014	597,447	77,172	7.741759 
 9/30/2014	614,670	80,777	7.609468 
 9/15/2014	706,223	30,050	23.501597 
 8/29/2014	696,171	24,195	28.773342 
 7/31/2014	757,083	19,833	38.172894 
 7/15/2014	735,381	26,349	27.909257 
 6/30/2014	579,031	99,257	5.833654 
 6/13/2014	552,640	26,016	21.242312 
 5/30/2014	585,341	33,460	17.493754 
 5/15/2014	605,400	31,726	19.082141 
 4/30/2014	580,025	39,541	14.668951 
 4/15/2014	616,988	53,891	11.448813 
 3/31/2014	588,757	79,412	7.413955 
 3/14/2014	529,358	76,648	6.906351 
  
 2/28/2014 533,097 59,926 8.895922 
 2/14/2014 565,697 51,512 10.981849 
 1/31/2014 539,420 57,610 9.363305 
 1/15/2014 558,592 65,934 8.471987 
 12/31/2013 554,649 83,294 6.658931 
 12/13/2013 393,873 26,321 14.964211 
 11/29/2013 371,134 50,624 7.331187 
 11/15/2013 292,485 55,998 5.223133 
 10/31/2013 272,912 46,280 5.896975 
 10/15/2013 246,998 65,891 3.748585 
 9/30/2013 112,656 152,715 1.000000 
 9/13/2013 117,578 60,484 1.943952 
 

Read more: http://www.nasdaq.com/symbol/icel/short-interest#ixzz3Cr7dbkPI

[LORTAP KCOTS]

Glad I waited on this one.. Technology is great here, but still needs more financing???

[XenaLives]

This one sure is flying under the radar:

October 27, 2014
Photo Release -- Cellular Dynamics Awarded $1.2 Million NEI Contract for Developing Patient-Derived Stem Cells in Gear-Up for Age-Related Macular Degeneration Trial

MADISON, Wis., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Cellular Dynamics International (CDI) (Nasdaq:ICEL), today announced that the National Eye Institute (NEI), a division of the National Institutes of Health (NIH), awarded the company a $1.2 million contract to manufacture clinically compatible induced pluripotent stem cells (iPSCs) and iPSC-derived human retinal pigment epithelial (RPE) cells. These cells will be manufactured from individuals suffering from dry age-related macular degeneration (AMD) and will be used for investigational new drug (IND) enabling studies. Once the IND is approved, the same procedures will be used to generate clinical-grade iPSC-derived RPE tissue for transplantation into AMD patients. This process, known as autologous cellular therapy, would be the first of its kind in the U.S.
Human iPSC-derived RPE cells
Human iPSC-derived RPE cells (right, micrograph), here grown on a scaffold (left, artist rendered). The microvilli, or little projections on the surface of each RPE cell, communicate with the photoreceptors in the eye, an essential interaction for sight. Courtesy of Nathan Hotaling (NIST), Vladimir Khristov and Kapil Bharti (NEI).


A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=28623

CDI will use its expertise to reprogram skin and blood samples from individuals with AMD to create clinically compatible, autologous iPSCs, which are genetically identical to the individual. As a genetic match to the patient, these cells are intended to reduce the risk of transplant rejection. NEI researchers plan to use these cells as part of their pre-clinical process to develop the first autologous cell transplantation treatment for dry AMD.

Key points:

The clinically compatible RPE cells resulting from CDI's protocol development and optimization, when manufactured under cGMP conditions, would likely be the first iPSC-based, autologous cellular therapeutic candidates transplanted into humans in a Phase I clinical trial in the U.S.
The contract funds the manufacture of clinically compatible iPSCs and the development and manufacture of clinically compatible iPSC-derived human RPE cells by CDI. The RPE manufacturing process is based on iPSC-RPE differentiation methods developed and authenticated by NEI.
CDI will use existing NEI differentiation protocols to develop and optimize the methods for manufacturing RPE cells and provide NEI with cGMP-ready protocols and training for their manufacture.
Researchers at NEI will use the RPE cells that CDI manufactures for preclinical studies in preparation for a clinical trial that will test these cells in patients with dry AMD. AMD is the leading cause of vision loss in people aged 60 and older, and as many as 11 million Americans have some form of macular degeneration, according to the Bright Focus Foundation.
There are currently no FDA-approved therapies for dry AMD, which accounts for about 90% of AMD cases. Therapies for wet AMD require repeated eye injections that slow or, at best, arrest disease progression. Revenues for wet AMD products were more than $5.75 billion in 2013.

Quotes:

Bob Palay, chief executive officer of CDI, said, "AMD is a debilitating disease. It begins with vision loss in the center of the visual field and often progresses to nearly total vision loss. CDI is delighted to be selected by the NEI to develop autologous RPEs for treatment of AMD. Our goal is to provide Dr. Bharti and his fellow medical researchers with transplantable manufactured RPEs for the treatment of this major cause of blindness. We are excited to enable these researchers' efforts to help patients regain their vision."

Chris Parker, chief commercial officer of CDI, said, "CDI has a unique ability to consistently manufacture large numbers of iPSCs and human cells to very tight specifications, including under cGMP conditions. CDI's reprogramming platform enables us to develop autologous iPSC-based therapies, which would be a first in the U.S. We look forward to working with the NEI to successfully complete this work and progress through Phase I clinical development."

Sheldon Miller, Ph.D., Scientific Director at the NEI, said, "This is a first step towards our phase I IND enabling studies. There are a small number of facilities in the U.S. with the capacity to generate iPSCs and differentiate them into multiple lineages. We are eager to begin testing clinically compatible patient-derived RPE cells in laboratory models of retinal degeneration."

Kapil Bharti, Ph.D., Earl Stadtman Investigator and lead scientist on this project at NEI, said, "All of us at NEI, including the basic research, preclinical, and clinical teams, are committed to the success of this IND. We are grateful to the NIH Common Fund and the NEI Intramural Program for their support."

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications. CDI's proprietary iCell Operating System (iCell® O/S) includes true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell® Products). CDI's iCell O/S products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use our iCell O/S products, among other purposes, for drug discovery and screening; to test the safety and efficacy of their small molecule and biologic drug candidates; for stem cell banking; and in the research and development of cellular therapeutics. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin, with a second facility in Novato, California. See www.cellulardynamics.com.

Follow us on Twitter @CellDynamics or www.twitter.com/celldynamics

http://investors.cellulardynamics.com/releasedetail.cfm?ReleaseID=878285

[LORTAP KCOTS]

Implosion.

[alexwv]

Rally coming! Chart is pointing north!

[XenaLives]

This stock has always been extremely controlled. There are conflicting indicators in the last week. The run down seems to be orchestrated, by whom is the question.

As for the financing, they got a production patent - not a big leap to think that they would need to finance production. This does not necessarily lower the value of the enterprise.

I hear the pitter patter of little feet in the background.

[LORTAP KCOTS]

I'm dam good at this...

[XenaLives]

Shelf offering doesn't seem to be a bad thing - found two biotechs that did very well after a shelf offering.

The company now has patents and people who want cells. Money spent wisely on increasing production capacity will make the stock go up.

ICEL also has a large short position that has not been able to make a graceful exit so IMO there is a market....

 
 Settlement Date	Short Interest	Avg Daily Share Volume	Days To Cover 
 8/15/2014	685,856	27,148	25.263592 
 7/31/2014	757,083	19,833	38.172894 
 7/15/2014	735,381	26,349	27.909257 
 6/30/2014	579,031	99,257	5.833654 
 6/13/2014	552,640	26,016	21.242312 
 5/30/2014	585,341	33,460	17.493754 
 5/15/2014	605,400	31,726	19.082141 
 4/30/2014	580,025	39,541	14.668951 
 4/15/2014	616,988	53,891	11.448813 
 3/31/2014	588,757	79,412	7.413955 
 3/14/2014	529,358	76,648	6.906351 
 2/28/2014	533,097	59,926	8.895922 
 2/14/2014	565,697	51,512	10.981849 
 1/31/2014	539,420	57,610	9.363305 
 1/15/2014	558,592	65,934	8.471987 
 12/31/2013	554,649	83,294	6.658931 
 12/13/2013	393,873	26,321	14.964211 
 11/29/2013	371,134	50,624	7.331187 
 11/15/2013	292,485	55,998	5.223133 
 10/31/2013	272,912	46,280	5.896975 
 10/15/2013	246,998	65,891	3.748585 
 9/30/2013	112,656	152,715	1.000000 
 9/13/2013	117,578	60,484	1.943952 
  
 Read more: http://www.nasdaq.com/symbol/icel/short-interest#ixzz3Cr7dbkPI 
  
 

[XenaLives]

Link to SEC filing -

http://www.sec.gov/Archives/edgar/data/1482080/000148208014000048/cdi2014s308252014.htm#s380caf47a3434278b9324c7b31d084f6

[XenaLives]

Cellular Dynamics International Inc., a publicly traded maker of human cells in industrial quantities, has filed a registration statement with federal securities regulators for the sale of as much as $90 million worth of its stock, U.S. Securities and Exchange Commission documents show.

The Madison company used a shelf registration process, meaning the company may sell the shares to the public "from time to time." CDI would use the net proceeds for general corporate purposes, which may include working capital or capital expenditures.

CDI makes iPS, or human induced pluripotent stem cells and tissue cells. Like embryonic stem cells, these powerful cells can be grown into any of the body's cell types.

The company said late last month it had been granted a U.S. patent on the automated production of cells that can be grown into any of the more than 200 types of cells in the body. The patent positions CDI as the leading supplier of choice for scientists seeking a high-quality, reliable supply of human cells to use for research into new drugs and therapies, and stem cell banking, executives said.

http://www.jsonline.com/business/cellular-dynamics-registers-to-sell-up-to-90-million-in-stock-b99344604z1-273955681.html

[alwaysdreaming]

You are truly a piece of work, up at 5am creating fear so that you can make a buck.

After the news yesterday you didn't say squat coz you were too busy selling in anticipation of pulling off your plan today.

[noretreat]

The daily volume here is microscopic. Once the stock starts to trade a little it will run.

[noretreat]

Long term holders control the stock, IMO.

[noretreat]

Still hasn't hit the absolute floor of 9.50.

[noretreat]

This stock is poised for another run similar to the one just after the IPO

[XenaLives]

Lots of paint on this puppy...

08/28/14	09:25:00	10.86	10.61	13.87	0 
 08/28/14	09:29:44	10.86	10.61	13.87	0 
 08/28/14	09:29:44	10.84	10.61	13.87	-19304 
 08/28/14	09:30:00	10.84	10.78	11.07	0 
 08/28/14	09:30:00	10.81	10.78	11.07	100 
 08/28/14	09:30:07	10.81	10.78	11.52	0 
 08/28/14	09:30:07	10.81	10.78	11.74	0 
 08/28/14	09:30:08	10.81	10.78	11.80	0 
 08/28/14	09:31:04	10.81	10.78	11.80	0 
 08/28/14	09:31:20	10.81	10.79	11.80	0 
 08/28/14	09:31:40	10.81	10.80	11.80	0 
 08/28/14	09:31:43	10.81	10.79	11.80	0 
 08/28/14	09:32:11	10.81	10.80	11.80	0 
 08/28/14	09:32:11	10.81	10.79	11.79	0 
 08/28/14	09:32:14	10.81	10.80	11.79	0 
 08/28/14	09:32:35	10.81	10.79	11.79	0 
 08/28/14	09:33:04	10.81	10.79	11.77	0 
 08/28/14	09:33:15	10.81	10.79	11.11	0 
 08/28/14	09:33:15	10.80	10.79	11.11	200 
 08/28/14	09:34:02	10.80	10.79	11.10	0 
 08/28/14	09:35:00	10.80	10.79	11.10	0 
 08/28/14	09:36:35	10.80	10.79	11.09	0 
 08/28/14	09:37:00	10.80	10.79	11.09	0 
 08/28/14	09:37:11	10.80	10.79	11.08	0 
 08/28/14	09:37:12	10.80	10.79	11.07	0 
 08/28/14	09:37:31	10.80	10.79	11.07	0 
 08/28/14	09:38:14	10.80	10.79	11.05	0 
 08/28/14	09:38:15	10.80	10.79	10.95	0 
 08/28/14	09:38:31	10.80	10.79	10.95	0 
 08/28/14	09:39:10	10.80	10.79	10.94	0 
 08/28/14	09:40:00	10.79	10.79	10.89	59 
 08/28/14	09:41:19	10.79	10.79	10.89	0 
 08/28/14	09:42:53	10.79	10.78	10.89	100 
 08/28/14	09:43:37	10.79	10.78	10.89	0 
 08/28/14	09:47:10	10.78	10.65	10.85	409 
 08/28/14	09:47:32	10.78	10.65	10.84	0 
 08/28/14	09:47:37	10.78	10.61	10.79	0 
 08/28/14	09:47:37	10.65	10.61	10.79	5 
 08/28/14	09:51:26	10.79	10.64	10.96	458 
 08/28/14	09:54:57	10.66	10.62	11.01	100 
 08/28/14	09:55:43	10.66	10.62	11.01	0 
 08/28/14	10:00:03	10.63	10.62	11.01	328 
 08/28/14	10:21:54	10.66	10.61	10.96	322 
 08/28/14	10:23:43	10.66	10.63	10.96	0 
 08/28/14	10:24:33	10.66	10.63	10.96	0 
 08/28/14	10:26:24	10.63	10.61	10.96	100 
 08/28/14	10:26:25	10.63	10.63	10.96	0 
 08/28/14	10:26:50	10.63	10.63	10.96	0 
 08/28/14	10:27:53	10.63	10.63	10.95	0 
 08/28/14	10:29:57	10.63	10.63	10.95	0 
 08/28/14	10:32:50	10.63	10.61	10.80	0 
 08/28/14	10:32:50	10.62	10.61	10.80	100 
 08/28/14	10:42:02	10.62	10.61	10.80	0 
 08/28/14	10:42:02	10.6101	10.61	10.80	600 
 08/28/14	10:53:32	10.62	10.61	10.80	100 
 08/28/14	11:03:55	10.62	10.61	10.62	0 
 08/28/14	11:03:56	10.61	10.61	10.80	106 
 08/28/14	11:03:56	10.61	10.61	10.80	2 
 08/28/14	11:03:56	10.61	10.61	10.80	2 
 08/28/14	11:03:56	10.61	10.61	10.80	1 
 08/28/14	11:14:41	10.61	10.61	10.62	0 
 08/28/14	11:14:41	10.62	10.61	10.62	100 
 08/28/14	11:15:18	10.62	10.61	10.76	100 
 08/28/14	11:15:20	10.62	10.61	10.80	0 
 08/28/14	11:15:20	10.61	10.61	10.80	5 
 08/28/14	11:23:20	10.61	10.61	10.62	0 
 08/28/14	11:24:12	10.61	10.51	10.62	1179 
 08/28/14	11:24:12	10.51	10.51	10.62	5 
 08/28/14	11:25:18	10.51	10.51	10.62	0 
 08/28/14	11:29:20	10.51	10.51	10.62	5 
 08/28/14	11:29:20	10.565	10.51	10.62	100 
 08/28/14	11:29:20	10.51	10.51	10.62	5 
 08/28/14	11:36:04	10.49	10.49	10.62	5 
 08/28/14	11:42:08	10.49	10.45	10.62	100 
 08/28/14	11:42:08	10.47	10.45	10.62	5 
 08/28/14	11:44:21	10.47	10.45	10.62	0 
 08/28/14	11:48:50	10.45	10.45	10.62	4 
 08/28/14	11:48:50	10.47	10.45	10.62	100 
 08/28/14	11:48:50	10.45	10.45	10.62	2 
 08/28/14	11:48:50	10.45	10.45	10.62	1 
 08/28/14	11:54:30	10.45	10.39	10.62	2 
 08/28/14	11:56:03	10.45	10.36	10.62	0 
 08/28/14	11:56:06	10.45	10.36	10.62	0 
 08/28/14	12:00:44	10.61	10.36	10.62	100 
 08/28/14	12:01:09	10.61	10.37	10.62	0 
 08/28/14	12:01:32	10.61	10.37	10.62	0 
 08/28/14	12:03:34	10.37	10.37	10.62	100 
 08/28/14	12:03:49	10.37	10.32	10.61	0 
 08/28/14	12:03:53	10.37	10.32	10.61	0 
 08/28/14	12:04:11	10.37	10.31	10.61	0 
 08/28/14	12:04:11	10.31	10.31	10.61	101 
 08/28/14	12:04:11	10.3101	10.31	10.61	200 
 08/28/14	12:08:36	10.3101	10.31	10.61	0 
 08/28/14	12:09:38	10.3101	10.32	10.61	0 
 08/28/14	12:10:57	10.3101	10.32	10.61	0 
 08/28/14	12:10:57	10.33	10.32	10.61	100 
 08/28/14	12:18:11	10.33	10.33	10.61	0 
 08/28/14	12:18:13	10.33	10.33	10.62	0 
 08/28/14	12:18:38	10.33	10.33	10.62	0 
 08/28/14	12:18:41	10.33	10.34	10.62	0 
 08/28/14	12:24:58	10.33	10.34	10.72	0 
 08/28/14	12:25:00	10.33	10.34	10.71	0 
 08/28/14	12:28:04	10.35	10.34	10.71	100 
 08/28/14	12:28:17	10.35	10.35	10.71	0 
 08/28/14	12:28:55	10.35	10.36	10.71	0 
 08/28/14	12:28:55	10.35	10.36	10.70	0 
 08/28/14	12:29:05	10.35	10.36	10.70	0 
 08/28/14	12:34:27	10.35	10.36	10.72	0 
 08/28/14	12:38:24	10.39	10.36	10.71	100 
 08/28/14	12:38:32	10.39	10.37	10.71	0 
 08/28/14	12:38:35	10.39	10.37	10.72	0 
 08/28/14	12:38:38	10.39	10.37	10.72	0 
 08/28/14	12:39:05	10.39	10.38	10.72	0 
 08/28/14	12:40:11	10.39	10.39	10.72	0 
 08/28/14	12:41:05	10.39	10.40	10.72	0 
 08/28/14	12:42:43	10.39	10.40	10.72	0 
 08/28/14	12:44:55	10.39	10.41	10.72	0 
 08/28/14	12:54:28	10.69	10.44	10.78	200 
 08/28/14	12:54:41	10.69	10.44	10.78	0 
 08/28/14	12:55:01	10.69	10.46	10.78	0 
 08/28/14	12:56:01	10.69	10.48	10.80	0 
 08/28/14	12:57:04	10.69	10.49	10.80	0 
 08/28/14	12:57:05	10.69	10.50	10.80	0 
 08/28/14	12:57:30	10.69	10.49	10.80	0 
 08/28/14	12:57:30	10.69	10.50	10.80	0 
 08/28/14	12:57:55	10.69	10.50	10.80	0 
 08/28/14	12:58:03	10.69	10.51	10.80	0 
 08/28/14	12:58:13	10.69	10.51	10.80	0 
 08/28/14	13:03:09	10.53	10.36	10.55	105 
 08/28/14	13:03:32	10.53	10.37	10.55	95 
 08/28/14	13:03:52	10.53	10.37	10.55	0 
 08/28/14	13:04:25	10.37	10.37	10.55	45 
 08/28/14	13:08:59	10.37	10.37	10.55	0 
 08/28/14	13:10:02	10.37	10.37	10.55	100 
 08/28/14	13:17:43	10.37	10.37	10.55	0 
 08/28/14	13:17:53	10.37	10.41	10.55	0 
 08/28/14	13:18:04	10.37	10.41	10.55	0 
 08/28/14	13:18:28	10.37	10.45	10.55	0 
 08/28/14	13:18:28	10.55	10.45	10.55	1 
 08/28/14	13:18:28	10.55	10.45	10.55	1 
 08/28/14	13:24:52	10.55	10.45	10.55	0 
 08/28/14	13:26:30	10.45	10.45	10.55	100 
 08/28/14	13:26:42	10.45	10.45	10.55	0 
 08/28/14	13:28:20	10.40	10.40	10.55	275 
 08/28/14	13:30:34	10.40	10.40	10.55	0 
 08/28/14	13:30:43	10.4001	10.40	10.55	50 
 08/28/14	13:38:09	10.54	10.42	10.55	200 
 08/28/14	13:47:24	10.41	10.40	10.55	100 
 08/28/14	13:49:00	10.41	10.40	10.55	0 
 08/28/14	13:54:00	10.44	10.40	10.72	400 
 08/28/14	13:58:42	10.44	10.40	10.71	0 
 08/28/14	13:58:51	10.44	10.40	10.71	0 
 08/28/14	13:58:51	10.40	10.40	10.71	20 
 08/28/14	14:01:19	10.40	10.40	10.50	0 
 08/28/14	14:01:34	10.40	10.40	10.50	0 
 08/28/14	14:02:51	10.41	10.40	10.50	148 
 08/28/14	14:06:24	10.41	10.40	10.50	0 
 08/28/14	14:11:59	10.40	10.36	10.50	125 
 08/28/14	14:11:59	10.37	10.36	10.50	2 
 08/28/14	14:14:47	10.37	10.36	10.50	0 
 08/28/14	14:16:19	10.36	10.36	10.50	100 
 08/28/14	14:19:43	10.36	10.36	10.50	0 
 08/28/14	14:22:28	10.34	10.31	10.39	200 
 08/28/14	14:22:32	10.36	10.31	10.39	5 
 08/28/14	14:23:01	10.36	10.31	10.39	0 
 08/28/14	14:25:29	10.31	10.34	10.39	100 
 08/28/14	14:25:29	10.38	10.34	10.39	100 
 08/28/14	14:25:29	10.38	10.34	10.39	200 
 08/28/14	14:26:19	10.34	10.34	10.39	100 
 08/28/14	14:26:30	10.34	10.34	10.39	0 
 08/28/14	14:27:55	10.39	10.34	10.50	100 
 08/28/14	14:27:55	10.34	10.34	10.50	100 
 08/28/14	14:27:55	10.50	10.34	10.50	100 
 08/28/14	14:27:55	10.50	10.34	10.50	300 
 08/28/14	14:36:19	10.50	10.34	10.50	500 
 08/28/14	14:40:12	10.50	10.34	10.50	200 
 08/28/14	14:41:30	10.47	10.36	10.67	100 
 08/28/14	14:42:24	10.47	10.37	10.67	0 
 08/28/14	14:42:39	10.47	10.34	10.67	0 
 08/28/14	14:43:10	10.47	10.34	10.68	0 
 08/28/14	14:43:12	10.47	10.34	10.67	0 
 08/28/14	14:43:38	10.47	10.34	10.67	0 
 08/28/14	14:43:47	10.47	10.34	10.50	0 
 08/28/14	14:46:19	10.34	10.34	10.50	100 
 08/28/14	14:47:29	10.34	10.34	10.50	0 
 08/28/14	14:47:59	10.35	10.34	10.50	100 
 08/28/14	14:47:59	10.48	10.34	10.50	200 
 08/28/14	14:51:19	10.34	10.33	10.50	100 
 08/28/14	14:51:19	10.50	10.33	10.50	200 
 08/28/14	14:51:19	10.49	10.33	10.50	100 
 08/28/14	14:54:22	10.50	10.33	10.50	200 
 08/28/14	14:55:31	10.50	10.34	10.50	100 
 08/28/14	14:55:49	10.50	10.33	10.50	0 
 08/28/14	14:55:51	10.50	10.34	10.50	0 
 08/28/14	14:56:10	10.50	10.34	10.50	0 
 08/28/14	14:56:41	10.50	10.34	10.50	200 
 08/28/14	14:57:47	10.50	10.34	10.50	200 
 08/28/14	14:57:47	10.50	10.33	10.50	0 
 08/28/14	14:57:47	10.50	10.33	10.50	100 
 08/28/14	14:57:47	10.33	10.33	10.50	10 
 08/28/14	14:59:59	10.50	10.33	10.50	200 
 08/28/14	15:03:14	10.50	10.33	10.50	500 
 08/28/14	15:03:14	10.50	10.33	10.50	100 
 08/28/14	15:05:20	10.50	10.34	10.50	200 
 08/28/14	15:05:30	10.50	10.35	10.50	0 
 08/28/14	15:05:31	10.50	10.34	10.50	0 
 08/28/14	15:05:34	10.50	10.36	10.50	0 
 08/28/14	15:05:35	10.50	10.34	10.50	0 
 08/28/14	15:05:54	10.50	10.34	10.50	0 
 08/28/14	15:06:24	10.50	10.35	10.50	200 
 08/28/14	15:07:25	10.50	10.35	10.50	100 
 08/28/14	15:08:27	10.50	10.35	10.50	200 
 08/28/14	15:08:37	10.50	10.35	10.50	0 
 08/28/14	15:09:28	10.50	10.35	10.50	200 
 08/28/14	15:09:28	10.50	10.35	10.50	100 
 08/28/14	15:10:31	10.50	10.36	10.50	0 
 08/28/14	15:11:41	10.50	10.36	10.50	200 
 08/28/14	15:12:30	10.50	10.36	10.50	100 
 08/28/14	15:12:44	10.50	10.38	10.50	0 
 08/28/14	15:12:45	10.50	10.33	10.50	0 
 08/28/14	15:13:29	10.50	10.33	10.63	200 
 08/28/14	15:13:40	10.50	10.33	10.63	1 
 08/28/14	15:14:05	10.50	10.33	10.62	0 
 08/28/14	15:14:14	10.62	10.33	10.63	100 
 08/28/14	15:14:19	10.62	10.33	10.63	0 
 08/28/14	15:14:19	10.60	10.33	10.63	100 
 08/28/14	15:14:39	10.61	10.33	10.63	100 
 08/28/14	15:14:39	10.34	10.33	10.63	100 
 08/28/14	15:17:43	10.34	10.33	10.63	0 
 08/28/14	15:17:50	10.34	10.40	10.63	0 
 08/28/14	15:17:57	10.34	10.44	10.63	0 
 08/28/14	15:18:04	10.49	10.40	10.69	100 
 08/28/14	15:18:04	10.69	10.40	10.69	50 
 08/28/14	15:21:39	10.41	10.40	10.69	100 
 08/28/14	15:21:44	10.41	10.40	10.69	0 
 08/28/14	15:23:11	10.4175	10.40	10.68	309 
 08/28/14	15:24:00	10.4175	10.40	10.68	0 
 08/28/14	15:29:29	10.40	10.40	10.67	92 
 08/28/14	15:29:29	10.43	10.40	10.67	100 
 08/28/14	15:29:29	10.43	10.40	10.67	6 
 08/28/14	15:29:29	10.43	10.40	10.67	94 
 08/28/14	16:01:16	10.58	10.45	13.88	4586 
 08/28/14	16:04:50	10.58	10.00	13.88	0 
 08/28/14	16:05:15	10.58	10.48	13.88	0 
 08/28/14	16:12:33	10.58	10.00	13.88	0 
 08/28/14	21:00:00	10.50	10.13	13.88	0 
 08/29/14	09:25:00	10.50	10.14	13.88	0 
 08/29/14	09:30:00	10.43	10.27	10.70	-18949 
 08/29/14	09:30:03	10.43	10.28	10.70	0 
 08/29/14	09:30:03	10.43	10.28	10.70	200 
 08/29/14	09:30:08	10.43	10.26	10.70	0 
 08/29/14	09:31:21	10.43	10.26	10.70	0 
 08/29/14	09:31:37	10.48	10.26	10.70	50 
 08/29/14	09:32:05	10.70	10.26	10.70	650 
 08/29/14	09:32:16	10.70	10.26	10.70	0 
 08/29/14	09:32:25	10.70	10.34	10.70	0 
 08/29/14	09:32:25	10.65	10.34	10.70	250 
 08/29/14	09:34:18	10.69	10.35	10.69	50 
 08/29/14	09:34:18	10.35	10.35	10.69	49 
 08/29/14	09:35:20	10.35	10.35	10.69	0 
 08/29/14	09:35:58	10.52	10.34	10.69	100 
 08/29/14	09:36:04	10.52	10.35	10.68	0 
 08/29/14	09:36:29	10.52	10.35	10.68	0 
 08/29/14	09:38:26	10.52	10.42	10.68	0 
 08/29/14	09:38:39	10.52	10.52	10.68	200 
 08/29/14	09:43:40	10.66	10.53	10.68	5 
 08/29/14	09:43:47	10.66	10.53	10.68	0 
 08/29/14	09:45:39	10.68	10.54	10.69	1332 
 08/29/14	09:45:39	10.52	10.75	11.13	342 
 08/29/14	09:49:12	10.52	10.78	11.13	0 
 08/29/14	09:51:49	10.52	10.78	11.12	0 
 08/29/14	09:53:32	11.0852	10.81	11.13	100 
 08/29/14	09:57:10	11.10	10.81	11.13	1000 
 08/29/14	09:57:38	11.10	10.82	11.13	0 
 08/29/14	09:58:33	10.93	10.81	11.13	100 
 08/29/14	09:58:35	10.93	10.93	11.13	0 
 08/29/14	10:05:30	11.06	10.93	11.06	100 
 08/29/14	10:13:15	11.06	10.93	11.06	0 
 08/29/14	10:20:20	11.06	10.93	11.00	0 
 08/29/14	10:20:26	11.06	10.93	11.00	0 
 08/29/14	10:21:03	10.93	10.76	10.98	200 
 08/29/14	10:22:30	10.93	10.76	10.98	0 
 08/29/14	10:33:24	10.77	10.75	10.98	2 
 08/29/14	10:34:36	10.77	10.76	10.98	0 
 08/29/14	10:36:20	10.77	10.76	10.98	0 
 08/29/14	10:40:00	10.77	10.75	10.98	0 
 08/29/14	10:40:21	10.77	10.75	10.98	0 
 08/29/14	10:40:35	10.77	10.76	10.98	0 
 08/29/14	10:40:41	10.77	10.75	10.98	0 
 08/29/14	10:41:01	10.77	10.76	10.98	0 
 

[XenaLives]

This is one of the most controlled stocks I've ever seen. A patent announcement doesn't move it out of the trading range - at least not so far today.....

Definitely not on the radar of retail...

[XenaLives]

LOL! 685856/6000 (today's volume)= 114 days to cover.

[XenaLives]

I've swing traded ICEL a couple of times this summer. It is highly manipulated and I think shorts are in big trouble here. It looks like half a million was shorted at the high and they have been unable to cover, instead they've dug the hole deeper or more skillful shorts/funds have laid off to the more ignorant.

I think almost all of the trading that does take place is wash trading. No shares changing hands.

News after labor day could really build a fire!!!

 
 8/15/2014	685,856	27,148	25.263592 
 7/31/2014	757,083	19,833	38.172894 
 7/15/2014	735,381	26,349	27.909257 
 6/30/2014	579,031	99,257	5.833654 
 6/13/2014	552,640	26,016	21.242312 
 5/30/2014	585,341	33,460	17.493754 
 5/15/2014	605,400	31,726	19.082141 
 4/30/2014	580,025	39,541	14.668951 
 4/15/2014	616,988	53,891	11.448813 
 3/31/2014	588,757	79,412	7.413955 
 3/14/2014	529,358	76,648	6.906351 
 2/28/2014	533,097	59,926	8.895922 
 2/14/2014	565,697	51,512	10.981849 
 1/31/2014	539,420	57,610	9.363305 
 1/15/2014	558,592	65,934	8.471987 
 12/31/2013	554,649	83,294	6.658931 
 12/13/2013	393,873	26,321	14.964211 
 11/29/201 3	371,134	50,624	7.331187 
 11/15/2013	292,485	55,998	5.223133 
 10/31/2013	272,912	46,280	5.896975 
 10/15/2013	246,998	65,891	3.748585 
 9/30/2013	112,656	152,715	1.000000 
 9/13/2013	117,578	60,484	1.943952 
 8/30/2013	92,742	47,825	1.939195 
 8/15/2013	59,763	117,314	1.000000 
  
 Read more: http://www.nasdaq.com/symbol/icel/short-interest#ixzz3BhlhqbmS 
 

[LORTAP KCOTS]

I'm watching this one, looks like at least another year before the company can be profitable. I fully expect at least one round of financing and a share price of $6.00 to be had at some point.

[noretreat]

http://investors.cellulardynamics.com/secfiling.cfm?filingid=892712-14-165&CIK=1482080

[noretreat]

ICEL 13g filing: http://archive.fast-edgar.com/20140123/A22ZW222Z22XJ2V2222U22N29NOPZZ22AH62

[noretreat]

Cellular Dynamics at JPM! up 2 bucks today and heading higher.

On January 10, 2014 Cellular Dynamics International, Inc. (“CDI”) issued a press release announcing that its Chief Executive Officer Bob Palay is scheduled to present at the 32 nd Annual J.P. Morgan Healthcare Conference at 4:30 p.m. PST, Tuesday, January 14, 2014.

CDI’s presentation will be webcast live at: http://jpmorgan.metameetings.com/confbook/healthcare14/directlink.php?ticker=ICEL

[noretreat]

Cellular Dynamics at JPM! up 2 bucks today and heading higher.

On January 10, 2014 Cellular Dynamics International, Inc. (“CDI”) issued a press release announcing that its Chief Executive Officer Bob Palay is scheduled to present at the 32 nd Annual J.P. Morgan Healthcare Conference at 4:30 p.m. PST, Tuesday, January 14, 2014.

CDI’s presentation will be webcast live at: http://jpmorgan.metameetings.com/confbook/healthcare14/directlink.php?ticker=ICEL

[SmurfVA]

ICEL reference on the iShares Nasdaq Biotechnology ETF (IBB)

Recent find on $heff board (http://investorshub.advfn.com/boards/read_msg.aspx?message_id=95020948)

Also Ref. http://seekingalpha.com/currents/post/1467381

Looking GOOD here ICEL!

[SmurfVA]

Looks like you might hit your target soon here !

[noretreat]

The Hamner Institutes and Cellular Dynamics Collaborate to Develop In Vitro Assays Using Human iPS Cell-Derived Hepatocytes
Collaboration Will Accelerate Innovative Toxicity Testing Research
RESEARCH TRIANGLE PARK, N.C. and MADISON, Wis., Dec. 9, 2013 (GLOBE NEWSWIRE) -- The Hamner Institutes for Health Sciences today announced a collaborative agreement with Cellular Dynamics International (CDI) to develop predictive in vitro screening assays for chemical, environmental and pharmaceutical toxicology assessments that utilize CDI's human induced pluripotent stem (iPS) cell-derived hepatocytes.

Current in vitro models of liver function employ immortalized cell lines, animal models and primary tissue isolates harvested from human cadavers. Each of these model systems presents limitations in functionality, reproducibility, translatability and availability.

Human iPS cell-derived hepatocytes could provide a consistent, reproducible and limitless source of liver tissue that reflects native liver function and may offer significant improvement over existing in vitro models.

CDI will provide iCell® Hepatocytes to The Hamner for use in an on-going program of research, referred to as "Toxicity Testing in the 21st Century: Toxicity Pathways and Network Biology." This program employs several prototypical toxicity pathway case studies to develop human cell-based assays that map and model key cell signaling pathways in order to evaluate dose response. These assays, once validated with prototype chemicals, should enable toxicity testing and risk assessments based solely on in vitro test results, without progressing to toxicity studies in intact animals.

These in vitro-based toxicity testing schemes will speed testing of both important compounds in commerce and new compounds coming into use. More rapid testing will also help assess the backlog of thousands of chemicals for which there is very limited toxicity test data. As these test technologies mature, they could also provide a means to speed drug discovery by providing assessments of safety far earlier in the drug development process.

The Hamner toxicity pathway research program is a pre-competitive, multi-organization partnership designed to advance an integrated systems biology approach to toxicity testing research. Partners sponsoring the research include Agilent Technologies Inc., Illumina, Dow Chemical, Dow Corning Corporation, ExxonMobil, Unilever and CropLife America member companies. The Long-Range Research Initiative (LRI) of the American Chemistry Council supported earlier stages of this research. CDI will join this consortium and will collaborate with Hamner scientists on technical aspects of assay development.

"The Hamner's multi-stakeholder toxicity testing program needs a variety of normal cell types for studying chemical toxicity in human cells. New iPS-cell technologies, spearheaded by CDI, promise to make many stem cell-derived products available to transform in vitro testing. We are particularly enthusiastic about the use of iCell Hepatocytes to create models of liver toxicity and for evaluating pathways of metabolism," said Dr. Melvin Andersen, project director at The Hamner. "More broadly, stem cell products enhance work on the whole suite of pathways of interest to our diverse partners. As other stem cell platforms develop, we can connect them sequentially and examine multi-day treatment for many tissues with realistic exposures. These iCell Hepatocytes and other emerging stem cell-based products provide great value for safety assessments for all our partners."

Chris Parker, chief commercial officer of CDI, said, "We are excited to be working with The Hamner and this consortium to work toward better predictivity of human response to chemical compounds. Current models miss toxicities that might only manifest themselves in a human cell model, or falsely misidentify toxicities for compounds that would be safe. Published studies have shown numerous examples of our human iPS cell-derived iCell products to be more predictive than comparison current cell models. Through this collaboration we hope to further improve the safety of chemical compounds as well as the efficiency of research studies."

A report of a recent review of The Hamner program "Toxicity Testing in the 21st Century: Toxicity Pathways and Network Biology" is available at www.thehamner.org/tt21c and provides a synopsis of the first prototype pathways serving as examples of this integrated systems biology approach to toxicity testing.

About The Hamner Institutes for Health Sciences

The Hamner Institutes for Health Sciences is a nonprofit translational biomedical research institute located on an open, multidisciplinary campus in North Carolina's Research Triangle Park. Building upon 35 years of research excellence in toxicology, The Hamner works on drug and chemical safety in collaboration with academic, corporate, and government partners. Novel technologies used at The Hamner include genomic and bioinformatic approaches for improving toxicity testing, in silico models for predictive toxicology, in vitro models that utilize human cells or cell lines to evaluate perturbations of cellular responses, and in vivo models to elucidate genes that play a role in susceptibility to drug-induced toxicities. For more information, visit http://www.thehamner.org.

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of induced pluripotent stem cell technologies for in vitro drug development, stem cell banking and in vivo cellular therapeutic research. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells in industrial quality, quantity and purity from any individual's induced pluripotent stem cell line created from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin, with a second facility in Novato, California. See www.cellulardynamics.com. Follow us on Twitter @CellDynamics or www.twitter.com/celldynamics

Forward-looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Cellular Dynamics International, Inc., including statements regarding our products and iPS-cell technologies, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our product development efforts, actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. Cellular Dynamics undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see Cellular Dynamics' quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 29, 2013, and as may be described from time to time in Cellular Dynamics' subsequent SEC filings.

CONTACT: MEDIA CONTACTS:



Cellular Dynamics International

Joleen Rau

Senior Director, Marketing & Communications

Cellular Dynamics International, Inc.

[phone]

[e-mail]

[noretreat]

Jain Foundation Signs Agreement With Cellular Dynamics to Create iPSC Lines From Patients With Muscular Dystrophies
Patient-Derived iPSC Lines Will be Used as Disease Models for Basic Research and Drug Discovery
SEATTLE and MADISON, Wis., Dec. 4, 2013 (GLOBE NEWSWIRE) -- The Jain Foundation, a non-profit organization whose mission is to cure muscular dystrophies caused by dysferlin protein deficiency, today announced the signing of a Master Service Agreement with Cellular Dynamics International (CDI) (Nasdaq:ICEL). CDI will create five induced pluripotent stem cell (iPSC) lines from patients with these dystrophies. As there are currently no effective treatments for these genetic disorders, establishing model iPSC lines is an important step toward developing new drugs and therapies for these patients. Terms of the agreement were not disclosed.

Dysferlin is a protein thought to be involved in skeletal muscle repair. Genetic defects in the gene that codes for the protein result in two types of muscular dystrophy: Limb-girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi muscular dystrophy 1 (MMD1). Symptoms include weakness and progressive muscle wasting, and onset typically occurs in young adults.

CDI will employ their MyCell® Products line to create LGMD2B/Miyoshi patient-derived iPSC lines. iPSC technology is based on reprogramming adult cells to a pluripotent stem cell state, whereby the resulting iPSCs, and the somatic cells derived from them, carry the genotypic backgrounds of the original donors and model the disease. A primary goal of the Jain Foundation is to use these disease models for drug discovery.

"iPSC technology promises to provide a path to better understand these devastating genetic diseases so that researchers can develop therapies," said Plavi Mittal, President and CEO of the Jain Foundation. "CDI's ability to make iPSCs at high quality and purity from any individual, including LGMD2B patients, will provide scientists new tools to understand and address these debilitating forms of muscular dystrophy. We look forward to working with CDI to develop the iPSC lines."

Bob Palay, Chairman and Chief Executive Officer of CDI, said, "This is the second agreement we have entered into with an organization focused on developing new therapies for muscular dystrophy, demonstrating that research partners are confident in leveraging CDI's technical expertise to accelerate their discoveries. CDI continues to be at the forefront of innovation and is developing additional cell types, including skeletal myoblasts that may be relevant to work supported by the Jain Foundation. We are excited that the Jain Foundation shares our vision that iPSC technology is a promising path forward to advance healthcare discoveries."

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development, cell therapy, tissue engineering and organ regeneration. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells from any individual's stem cell line in industrial quality, quantity and purity. CDI is accelerating the adoption of pluripotent stem cell technology, adapting its methods to fit into standard clinical practice by the creation of individual stem cell lines from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin. See www.cellulardynamics.com.

Follow us on Twitter @CellDynamics or www.twitter.com/celldynamics

[SmurfVA]

With you on $17 and beyond. As Buzz Lightyear's famous say "To Infinity and Beyond!"

[noretreat]

that would be excellent! right now I'll take 17....

[SmurfVA]

I see this stock in triple digits ... Perhaps 1-2 years.

[SmurfVA]

GO ICEL! "Cellular Dynamics International (ICEL), which is a developer of induced pluripotent stem cell technologies, is all set to enter into a definitive agreement with the California Institute of Regenerative Medicine, or CIRM, to create a human induced pluripotent stem cell (iPSC) biobank from 3,000 individuals. The CIRM will provide a grant of $16 million for the 3-year project."

[SmurfVA]

Anything potential excitements here?

[noretreat]

Cellular Dynamics International Reports Third Quarter 2013 Financial Results
Revenues More Than Double
MADISON, Wis., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Cellular Dynamics International, Inc. (CDI) (Nasdaq:ICEL), a developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today reported financial results for the third quarter ended September 30, 2013.

"Trailing twelve months revenue as of September 30, 2013, more than doubled when compared to the corresponding period last year as did trailing twelve month average sales to our top 10 customers. Revenue for the third quarter also more than doubled when compared to the same period last year, and this growth was achieved with record gross margin from product sales of 79%," said Bob Palay, Chairman and CEO of CDI. "A growing number of pharmaceutical companies are adopting CDI's products for their research programs. By the end of the third quarter of 2013 CDI had sold to 142 customers for the trailing twelve months compared to 115 customers for the same period last year. Our top 10 customers averaged $704,000 in revenue for the trailing twelve months ended September 30, 2013, up from $313,000 for the same period last year. We believe these results add to the growing evidence that our iCell® and MyCell® products are becoming an industry standard for manufactured human cells."

In addition, as recently announced, the Company received the Notice of Grant Award (NGA) from the California Institute of Regenerative Medicine (CIRM) to create a human induced pluripotent stem cell (iPSC) biobank from 3,000 individuals. Receipt of the NGA signifies the entry into a definitive agreement with CIRM and the initiation of funding for the $16 million project. This contract resulted from the CIRM grant award to CDI announced last March. The Company looks forward to the revenue from this contract contributing to our expected ongoing revenue growth in our base business.

Third Quarter 2013 Selected Financial Results

Revenue. Total revenues for the third quarter of 2013 were $2.5 million compared to $1.2 million for the third quarter of 2012, an increase of 108%. For the trailing twelve months ended September 30, 2013, total revenues were $10.7 million, compared to $4.6 million for the trailing twelve months ended September 30, 2012, an increase of 133%. Growth in total revenue is primarily attributable to growth in unit sales of the Company's iCell products and significant increases in revenue from collaborations under our center of excellence agreements with Eli Lilly and Company and AstraZeneca UK Limited.

Costs and expenses. Total costs and expenses (excluding cost of product sales) were $9.3 million for the third quarter of 2013 compared to $6.4 million for the third quarter of 2012, an increase of 45%. This growth is attributable principally to an increase in supplies expense within our research and development organization, an increase in staffing within our sales and marketing organization and to general and administrative costs attributable to or triggered by our initial public offering. Approximately $669,000 of general and administrative expenses in the third quarter of 2013 reflect compensation and fee arrangements made effective as of the IPO date but attributable to service in the first and second quarter of 2013. Additionally, the Company incurred approximately $240,000 for travel and other expenses incurred in connection with our IPO. Tempering those operating cost increases, cost of product sales as a percentage of product sales revenue declined from 27% in the third quarter of 2012 to 21% in the third quarter of 2013, for a record gross margin from product sales of 79%. This compares favorably to the third quarter of 2012 gross margin from product sales of 73%.

Net loss. For the third quarter of 2013, net loss was $7.5 million, or $0.62 per share, compared with a net loss of $5.5 million, or $3.16 per share, for the third quarter of 2012. Weighted average shares outstanding for the third quarter of 2013 was 12.1 million versus 1.7 million for the third quarter of 2012. The difference in weighted average shares outstanding is principally attributable to both the common shares issued in our IPO and the conversion of our Series A and Series B preferred stock to common shares immediately prior to the consummation of our IPO.

Cash and cash equivalents. At September 30, 2013, cash and cash equivalents totaled $68.6 million.

CDI will host a conference call and webcast at 8:00 a.m. EST, November 13, 2013. The conference call may be accessed by dialing [phone] for domestic callers and [phone] for international callers. Please specify to the operator that you would like to join the Cellular Dynamics Third Quarter 2013 Financial Results Call, or reference conference ID# 96066198. The conference call also will be webcast live under the investor relations section of CDI's website at www.cellulardynamics.com, and will be archived there following the call for approximately one year.

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of induced pluripotent stem cell technologies for in vitro drug development, stem cell banking and in vivo cellular therapeutic research. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells in industrial quality, quantity and purity from any individual's induced pluripotent stem cell line created from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin, with a second facility in Novato, California. See www.cellulardynamics.com.

Forward-looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Cellular Dynamics International, Inc., including statements regarding our revenue growth and market acceptance of our products, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our product development efforts, actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. Cellular Dynamics undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see Cellular Dynamics' quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 29, 2013, which risks are incorporated herein by reference, and as may be described from time to time in Cellular Dynamics' subsequent SEC filings.

[noretreat]

Nice gain today. Definitely back on the upswing.

[noretreat]

BIG NEWS! (missed this one completely)

Cellular Dynamics International announced today that the company has received the Notice of Grant Award (NGA) from the California Institute of Regenerative Medicine (CIRM) to create a human induced pluripotent stem cell (iPSC) biobank from 3,000 individuals. Receipt of the NGA signifies the entry into a definitive agreement with CIRM and the initiation of funding for the $16 million project.

CDI will create three iPSC lines for each of 3,000 healthy and diseased donors. Tissue samples will be taken from patients suffering from Alzheimer's disease, autism spectrum disorders, liver diseases, cardiovascular diseases, neuro-developmental disabilities such as cerebral palsy and infantile epilepsy, diseases of the eye, and/or respiratory diseases. CDI will generate the iPSCs using the episomal reprogramming method first developed by CDI, which reverts the adult cell to a stem cell state without integrating foreign DNA into the cell's genome. Thus the original biological integrity of the cell is maintained, an important consideration in the study of human disease.

"We are delighted to formally begin this important three-year project. We believe CIRM is building the largest iPSC bank in the world," said Bob Palay, Chairman and Chief Executive Officer of CDI. "Since CIRM announced the $16 million grant award, we have been constructing our laboratory and iPSC manufacturing facilities in leased space at the Buck Institute for Research on Aging as well as staffing this facility. We now look forward to the start of the project where we'll begin to receive samples and produce the iPSC lines."

Ellen Feigal, MD, Senior Vice President, Research and Development of CIRM, added, "CIRM's initiative will provide scientists access to cell lines representing the genetic variety within human diseases such as Alzheimer's, heart disease, lung fibrosis and autism to discover the nature and causes of underlying human diseases in a way not previously feasible, and accelerate the discovery and development of new therapies. We look forward to working with CDI in this critical initiative to provide a broad array of relevant human stem cell research materials to scientists in California and worldwide in an effort to revolutionize regenerative medicine research."

[Gratefullife]

Yep, it was a good trade when it pushed twenty after weakening, but uptrending stocks are the place to be, and the wind seems to have shifted here...keeping ICEL on watch.

[noretreat]

Hi WorstLuck. I am out of here for a while...likely until next year. Don't get me wrong, I like the company long-term. THe absolute floor here is 9.50, and there should be strong support at $13. I'll get back in large if either of those hold for a while.

RUMOR ONLY: There may be some interesting news coming about re-generating islet cells for natural insulin production in type one diabetics...heard it twice from completely different sources about a month apart.

[WorstLuck]

Any reentry target?

Still evaluating the company but looking at 13's as obvious support.

[noretreat]

two major patents issued, two weeks apart. Time for another run-up?

[noretreat]

Cellular Dynamics Issued U.S. Patent Covering Differentiation of iPS Cells Into Endothelial, Hematopoietic Cells
MADISON, Wis., Oct. 16, 2013 (GLOBE NEWSWIRE) -- Cellular Dynamics International (CDI) (Nasdaq:ICEL), announced today that the U.S. Patent and Trademark Office (PTO) issued Patent No. 8,557,580 entitled "Methods and Compositions for the Differentiation of Stem Cells" on October 15. The newly issued patent relates to the method by which induced pluripotent stem (iPS) cells are differentiated into the diverse types of endothelial (blood vessel) and hematopoietic (blood) cells.

This method is used by CDI for the creation of its iCell® and MyCell® Products and enables the production of high quality cells at industrial volumes. Endothelial cells are important for the study of vascular disease research and therapy, including atherosclerosis (the build-up of plaques within blood vessels that can lead to tissue damage and even death), the body's inflammatory responses to general injury, and the generation of new blood vessels and tissues during healing. Hematopoietic cells include a diverse set of cell types, including erythroid cells (red blood cells), lymphocytes (white blood cells), and myelocytes (bone marrow cells). Readily available, high quality sources of these cells may lead to improvements in many clinical settings including cell-based therapies, cancer treatments, organ transplantation, and treatment for autoimmune diseases.

Bob Palay, chairman and chief executive officer of CDI, said, "CDI is committed to innovation and working to create the tissue cells critical to research impacting human health. This patent covers a reliable, scalable method for creating a consistent supply of blood and blood vessel cells in high quality, quantity and purity from iPS cells and continues CDI's intellectual property strategy of assembling a broad portfolio of patents and licenses for all of our products."

This is the fifth patent issued to CDI this year, adding to an intellectual property portfolio of over 700 patents.

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of induced pluripotent stem cell technologies for in vitro drug development, stem cell banking and in vivo cellular therapeutic research. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells in industrial quality, quantity and purity from any individual's induced pluripotent stem cell line created from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin, with a second facility in Novato, California. See www.cellulardynamics.com.

Follow us on Twitter @CellDynamics or www.twitter.com/celldynamics

Forward-looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Cellular Dynamics International, Inc., including the impact of the issuance of U.S. Patent No. 8,557,580, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our product development efforts, actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. Cellular Dynamics undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see Cellular Dynamic's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 29, 2013.

CONTACT: MEDIA CONTACTS:

Joleen Rau

Senior Director, Marketing & Communications

Cellular Dynamics International, Inc.

[phone]

[e-mail]



Robert E. Flamm, Ph.D.

Russo Partners LLC

212-845-4226

[noretreat]

basis plus taken off recently.

[noretreat]

Cellular Dynamics Issued U.S. Patent Covering iPSC Episomal Reprogramming
Episomes Reprogram Adult Tissue Cells to Stem Cell State, Opening the Door to Therapeutic Research and Clinical Use 10/02 07:00 AM

--------------------------------------------------------------------------------

MADISON, Wis., Oct. 2, 2013 (GLOBE NEWSWIRE) -- Cellular Dynamics International (ICEL:$18.87,00$0.46,002.50%) , announced today that the U.S. Patent and Trademark Office (PTO) issued Patent No. 8,546,140 entitled "Methods for the Production of iPS Cells Using Non-Viral Approach" on October 1. The newly issued patent relates to the method by which adult tissue cells, such as blood or skin, are reprogrammed into induced pluripotent stem (iPS) cells by the insertion of episomal vectors. This method is used by CDI for the creation of its iCell® and MyCell® Products. This episomal reprogramming patent has a term extending through May 2030.

Episomal vectors used in reprogramming are circular pieces of DNA that, when introduced into adult tissue cells, express genes known as reprogramming factors that drive the adult tissue cells back to a stem cell state, before then exiting the cell. This non-integrating methodology alleviates major safety concerns over the potential use of iPS-derived cells as therapeutics and removes a significant barrier for applying the technology in a clinical setting. Episomal reprogramming already has been performed to Good Manufacturing Practice (GMP) standards, a prerequisite for use of these cells in clinical applications.

In comparison, the original reprogramming method, published in 2007, uses viral vectors to insert four genes into the adult tissue cell's DNA. These genes integrate directly into the cell's genome. Concerns have arisen over the potential risks associated with this insertion of foreign DNA into the cell's genome, including insertion defects and errors that could lead to tumors.

Invented by CDI scientists, the episomal reprogramming method was first published in 2009 by James Thomson, V.M.D., Ph.D., founder and chief scientific officer and Junying Yu, Ph.D., senior director, advanced development programs at CDI, in Science. Since this publication, over 275 peer-reviewed scientific papers have cited this seminal paper on the episomal reprogramming method, indicating it is one of the most widely used methods for producing iPSCs.

"What is particularly noteworthy with the episomal method is that foreign DNA is not integrated into the genome of the cell during the reprogramming process," said Thomson. "Thus, the original biological integrity of the cell is maintained. This reprogramming method has been widely adopted by leaders in the field to create differentiated tissue cell types, such as cardiomyocytes, neurons and hepatocytes, to better understand human disease, test the efficacy and safety of drug candidates and most importantly develop therapeutic applications."

Bob Palay, chairman and chief executive officer of CDI, said, "The episomal reprogramming method has been widely adopted for research into therapeutic applications of iPS cell technology. Dr. Thomson's and CDI's goal has been to make stem cell technology widely available and easy to use. Toward that end we launched an episomal reprogramming kit, including Episomal iPSC Reprogramming Vectors, Vitronectin, and Essential 8™ Medium, that we began distributing through Life Technologies in 2012. The issuance of this patent to CDI ensures the continued broad availability of this critical technology."

CDI also holds an exclusive license from the Wisconsin Alumni Research Foundation (WARF) to the only other episomal reprogramming patent, which covers methodology that was invented at the University of Wisconsin by Thomson and Junying Yu.

Frequently asked questions regarding this patent, licensing information and episomal reprogramming technology l can be found on CDI's website, www.cellulardynamics.com/tech.

About Cellular Dynamics International, Inc. (ICEL:$18.87,00$0.46,002.50%)

Cellular Dynamics International, Inc. (ICEL:$18.87,00$0.46,002.50%) is a leading developer of induced pluripotent stem cell technologies for in vitro drug development, stem cell banking and in vivo cellular therapeutic research. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells in industrial quality, quantity and purity from any individual's induced pluripotent stem cell line created from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin, with a second facility in Novato, California. See www.cellulardynamics.com. Follow us on Twitter @CellDynamics or www.twitter.com/celldynamics

Forward-looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Cellular Dynamics International, Inc. (ICEL:$18.87,00$0.46,002.50%) , including the impact of the issuance of U.S. Patent No. 8,546,140 and episomal reprogramming, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our product development efforts, actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. Cellular Dynamics (ICEL:$18.87,00$0.46,002.50%) undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see Cellular Dynamic's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 29, 2013.

CONTACT: MEDIA CONTACTS:
Joleen Rau
Senior Director, Marketing & CommunicationsCellular Dynamics International, Inc. (ICEL:$18.87,00$0.46,002.50%)
310-5142
[e-mail]

Robert E. Flamm, Ph.D.
Russo Partners LLC
212-845-4226
[e-mail]

Investor Relations
Gitanjali Jain OgawaThe Trout Group, LLC
646 378-2949
[e-mail]

[Gratefullife]

ICEL has had good bid strength almost every day since it's IPO...

The other play, I tweeted Napodano a preview of my SA article and he tweeted all his followers "great article".... I felt validated